Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Bacterial Toxins01:12

Bacterial Toxins

108
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
108
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

954
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
954
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

565
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
565
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

825
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
825
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.5K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Two monosodium salt hydrates of Colour Index Pigment Red 48.

Acta crystallographica. Section C, Structural chemistry·2020
Same author

Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.

Journal of pharmacy practice·2017
Same author

Early Decompression following Cervical Spinal Cord Injury: Examining the Process of Care from Accident Scene to Surgery.

Journal of neurotrauma·2015
Same author

Costs and outcomes after cardiac surgery in patients refusing transfusion compared with those who do not: a case-matched study.

Transfusion·2015
Same author

Jehovah's Witnesses and cardiac surgery: a single institution's experience.

Transfusion·2014

Related Experiment Video

Updated: Apr 18, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.5K

Luminal Toxin-Binding Agents for Clostridium difficile Infection.

Ryan M McCoy1, Andrew Klick2, Steven Hill3

  • 1Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA RyanMcCoy@Creighton.edu.

Journal of Pharmacy Practice
|January 24, 2015
PubMed
Summary

Luminal toxin-binding agents (LTBAs) are not effective as monotherapy for Clostridium difficile infection (CDI). While potentially beneficial for recurrent CDI, more data is needed on their use alongside standard treatments.

Keywords:
Clostridium difficileanion-exchange resinscholestyraminecolestipolluminal toxin-binding agentstolevamer

More Related Videos

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.6K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.5K

Related Experiment Videos

Last Updated: Apr 18, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.5K
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.6K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.5K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Gastroenterology

Background:

  • Clostridium difficile infection (CDI) remains a significant healthcare challenge.
  • Luminal toxin-binding agents (LTBAs) have been explored as a treatment modality for CDI.
  • Current guidelines express concerns regarding LTBA use due to potential drug-drug interactions.

Purpose of the Study:

  • To systematically review existing literature on the efficacy of luminal toxin-binding agents (LTBAs) for Clostridium difficile infection (CDI).
  • To evaluate the role of LTBAs in CDI treatment, including monotherapy, adjunctive, and sequential approaches.

Main Methods:

  • Systematic literature search of PubMed and International Pharmaceutical Abstracts.
  • Inclusion criteria: English language articles, clinical outcomes, >5 adult human subjects with CDI treated with LTBAs.
  • Keywords included: anion-exchange resins, C difficile, cholestyramine, tolevamer, and colestipol.

Main Results:

  • LTBA monotherapy demonstrated inferiority to standard treatments like vancomycin and metronidazole for CDI.
  • Limited data exists on the efficacy of LTBAs as adjunctive or sequential therapy in contemporary practice.
  • Some evidence suggests potential benefit of LTBAs in reducing CDI recurrence.

Conclusions:

  • LTBA monotherapy is not recommended for treating CDI.
  • The efficacy of LTBAs as adjunctive or sequential therapy requires further investigation.
  • Additional research is necessary to clarify the role of LTBAs in CDI management, particularly concerning drug interactions with vancomycin.